No Data
Jiangsu Kanion Pharmaceutical (600557.SH): has cumulatively repurchased 2.1207% of shares.
On November 1st, Jiangsu Kanion Pharmaceutical (600557.SH) announced that as of October 31, 2024, the company has repurchased a total of 12,338,346 shares, accounting for 2.1207% of the current total share capital. The highest purchase price was 19.98 yuan/share, the lowest price was 11.77 yuan/share, and the total amount paid was 185,909,622.90 yuan (including transaction fees).
Kangyuan Pharmaceutical: Report for the Third Quarter of 2024 by Jiangsu Kangyuan Pharmaceutical Co., Ltd.
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on the main operating data for the first three quarters of 2024
Jiangsu Kangyuan Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Jiangsu Kanion Pharmaceutical (600557.SH) released its performance for the first three quarters, with a net income of 0.357 billion yuan, a year-on-year growth of 2.18%.
Jiangsu Kanion Pharmaceutical (600557.SH) disclosed its third quarter report for 2024, achieving a revenue of 31...
Jiangsu Kanion Pharmaceutical (600557.SH): The net income in the first three quarters was 0.357 billion yuan, an increase of 2.18% year-on-year.
Kangyuan Pharmaceutical (600557.SH) announced on October 30 that it achieved revenue of 3.11 billion yuan in the first three quarters of 2024, a decrease of 11.06% year-on-year; the net income attributable to shareholders of the listed company was 0.357 billion yuan, an increase of 2.18% year-on-year, with a basic earnings per share of 0.62 yuan.
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive EnoughNo Data
No Data
